All In Biotech

NDA 020287 · Pfizer

Fragmin

Dalteparin Sodium · Injection, Subcutaneous

Novel

Last checked: Nov 20, 2026Latest source record: Oct 24, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1994

Dec 22, 1994

Approved uses

8

Original approval plus efficacy supplements

Registered trials

664

227 Phase 3, 66 recruiting

FAERS reports

10,659

9,759 serious, 2,313 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SPINAL/EPIDURAL HEMATOMAS Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: • Use of indwelling epidural catheters • Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants. • A history of traumatic or repeated epidural or spinal punctures • A history of spinal deformity or spinal surgery • Optimal timing between the administration of FRAGMIN and neuraxial procedures is not known Monitor patients...

What it is approved for

From the label in effect Sep 30, 2025.

FRAGMIN is a low molecular weight heparin (LMWH) indicated for • Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction ( 1.1 ) • Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery or medical patients with severely restricted mobility during acute illness ( 1.2 ) • Extended treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in adult patients with cancer. In these patients, the FRAGMIN therapy begins with the initial VTE treatment and continues for six months ( 1.3 ) • Treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in pediatric patients from birth (gestational age at least 35 weeks) ( 1.4 ) • Limitations of Use FRAGMIN is not indicated for the acute treatment of VTE ( 1.5 ) 1.1 Prophylaxis of Ischemic Complications in Unstable Angina and Non-Q-Wave Myocardial Infarction FRAGMIN Injection is indicated for the prophylaxis of ischemic complications in unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin therapy [see Clinical Studies (14.1) ] . 1.2 Prophylaxis of Deep Vein Thrombosis FRAGMIN is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE): • In patients undergoing hip replacement surgery [see Clinical Studies (14.2) ] ; • In patients undergoing abdominal surgery who are at risk for thromboembolic complications [see Clinical Studies (14.3) ] ; • In medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness [see Clinical Studies (14.4) ] . 1.3 Extended Treatment of Symptomatic Venous Thromboembolism (VTE) in Adult Patients with Cancer FRAGMIN is indicated for the extended...

Mechanism: Dalteparin is a low molecular weight heparin with antithrombotic properties. It acts by enhancing the inhibition of Factor Xa and thrombin by antithrombin. In humans, dalteparin potentiates preferentially the inhibition of coagulation Factor Xa, while only slightly affecting the activated partial thromboplastin time (APTT).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

12 products under this application
  • FRAGMIN · DALTEPARIN SODIUM 7,500 IU/0.75ML · INJECTABLE, INJECTION · Discontinued
  • FRAGMIN · DALTEPARIN SODIUM 95,000IU/3.8ML (25,000IU/ML) · INJECTABLE, SUBCUTANEOUS · Prescription
  • FRAGMIN · DALTEPARIN SODIUM 10,000IU/4ML (2,500IU/ML) · INJECTABLE, SUBCUTANEOUS · Prescription
  • FRAGMIN · DALTEPARIN SODIUM 10,000IU/ML (10,000IU/ML) · INJECTABLE, SUBCUTANEOUS · Prescription
  • FRAGMIN · DALTEPARIN SODIUM 15,000IU/0.6ML (25,000IU/ML) · INJECTABLE, SUBCUTANEOUS · Prescription
  • FRAGMIN · DALTEPARIN SODIUM 10,000IU/0.4ML (25,000IU/ML) · INJECTABLE, SUBCUTANEOUS · Discontinued
  • FRAGMIN · DALTEPARIN SODIUM 12,500IU/0.5ML (25,000IU/ML) · INJECTABLE, SUBCUTANEOUS · Prescription
  • FRAGMIN · DALTEPARIN SODIUM 95,000IU/9.5ML (10,000IU/ML) · INJECTABLE, SUBCUTANEOUS · Discontinued
  • FRAGMIN · DALTEPARIN SODIUM 7,500IU/0.3ML (25,000IU/ML) · INJECTABLE, SUBCUTANEOUS · Prescription
  • FRAGMIN · DALTEPARIN SODIUM 18,000IU/0.72ML (25,000IU/ML) · INJECTABLE, SUBCUTANEOUS · Prescription
  • FRAGMIN · DALTEPARIN SODIUM 5,000IU/0.2ML (25,000IU/ML) · INJECTABLE, SUBCUTANEOUS · Prescription
  • FRAGMIN · DALTEPARIN SODIUM 2,500IU/0.2ML (12,500IU/ML) · INJECTABLE, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Dalteparin" as an intervention, any sponsor and status, largest first.

All 664 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea720
  • off label use714
  • pulmonary embolism618
  • dyspnoea603
  • vomiting586
  • abdominal pain537
  • sepsis513
  • pyrexia501
  • general physical health deterioration477
  • diarrhoea461
  • fatigue461
  • anaemia458

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004192
2005182
2006205
2007233
2008219
2009339
2010399
2011505
2012572
2013390
2014442
2015477
2016522
2017472
2018607
2019641
2020640
2021859
2022710
2023667
2024542
2025446
2026396

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Fragmin (Dalteparin Sodium,Porcine)

2024 spending

$1.8M

Beneficiaries

82

421 claims

Per beneficiary

$22,161

$246.71 per unit

View as table
YearSpending
2020$3,037,449
2021$2,351,703
2022$1,939,380
2023$2,204,099
2024$1,817,234

Part B: Fragmin (Dalteparin Sodium,porcine) · HCPCS J1645

2024 spending

$12K

Beneficiaries

20

155 claims

Per beneficiary

$577

2024 ASP limit $16.87 per unit

View as table
YearSpending
2020$66,328
2021$25,496
2022$18,280
2023$17,248
2024$11,544

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 410 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.